All Donum Therapeutics articles
-
NewsCARB-X funds UNSW Sydney to develop novel antibiotic targeting drug-resistant Gram negative bacterial infections
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$853k to UNSW Sydney to support the development of synthetic darobactin analogues, a new class of antibiotic designed to kill multidrug-resistant Gram-negative bacteria.